Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up

Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up

The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks....

Full description

Bibliographic Details
Main Authors: Salvador García-Delpech, Patricia Udaondo, Alex Samir Fernández-Santodomingo, Damian García-Teillard
Format: Article
Language:English
Published: Karger Publishers 2022-08-01
Series:Case Reports in Ophthalmology
Subjects:
neurotrophic keratopathy
recombinant human nerve growth factor
cenegermin
Online Access:https://beta.karger.com/Article/FullText/525923

Internet

https://beta.karger.com/Article/FullText/525923

Similar Items